Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity.
Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages.
Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand.
Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in
mdx
mice.
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis.
Animal Model: | C57BL/6 mice (experimental autoimmune encephalomyelitis) |
Dosage: | 30 mg/kg |
Administration: | Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) |
Result: | Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |